Gabay Avraham, the Chief Financial Officer of Oramed Pharmaceuticals, has reported the sale of 20,000 shares of the company's common stock. This transaction occurred on October 1, 2026, and is part of a Rule 10b5-1 trading plan established by Avraham on March 30, 2026. Such sales can provide insights into the financial strategies of company executives and their outlook on the business.
Background
Gabay Avraham is associated with Oramed Pharmaceuticals Inc., a company listed under the Central Index Key 0001176309. The firm operates within the pharmaceutical preparations industry. As of October 2, 2026, the company is based in New York, NY, and has been actively filing various forms with the SEC, including recent disclosures that reflect ongoing trading activities.
What the Filing Says
The SEC filing indicates that Avraham sold 20,000 shares at a weighted average price of $4.510 per share. The transaction was coded as a disposition of shares under the SEC's rules. The filing states, "Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026." Following this transaction, Avraham retains ownership of 861,076 shares.
Impact
This sale may affect investor perceptions of Oramed Pharmaceuticals, particularly regarding the confidence of its executives in the company's future performance. Insider trading can often signal to the market how executives view their company's prospects. The pharmaceutical sector, characterized by rapid innovation and competition, may see varied reactions from investors based on such disclosures.
What's Next
The filing does not say what happens next.